The Balance Between the Therapeutic Efficacy and Safety of [177Lu]Lu-NeoB in a Preclinical Prostate Cancer Model
ConclusionsTreatment with [177Lu]Lu-NeoB is effective in a preclinical PCa model. Adjusting the administered dose could positively impact the risk-benefit balance as a higher dose might not lead to an increased therapeutic effect, but it may lead to an increase in toxicological effects in healthy organs such as the kidneys.
Source: Molecular Imaging and Biology - Category: Molecular Biology Source Type: research
More News: Biology | Cancer | Cancer & Oncology | CT Scan | Gastroenterology | Molecular Biology | Pancreas | Pancreatic Cancer | Prostate Cancer | SPECT | Study | Toxicology | Urology & Nephrology